Clinical Trial Update: Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study [EARLY_Phase 1]

View source ↗

Summary

An early-phase study evaluating whether exposing T cells to the PI3K inhibitor duvelisib can enhance immune profiles in patients with recurrent or refractory di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Duvelisib (duvelisib)

Snippet

Sponsor: Emory University | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | EARLY_Phase 1 | Status: COMPLETED